Baird lowered the firm’s price target on LivaNova to $55 from $57 and keeps a Neutral rating on the shares. The firm said its Q2 beat/raise suggests further 2024 upside, and the anticipated lower DTD-spend should represent an incremental 2025 benefit.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- LivaNova raises FY24 adjusted EPS view to $3.10-$3.20 from $3.05-$3.15
- LivaNova reports Q2 adjusted EPS 93c, consensus 78c
- LIVN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- LivaNova price target raised to $72 from $70 at Stifel
- Needham medtech & diagnostics analyst holds analyst/industry conference call